The Industry’s Leading Forum Advancing CNS Drug Delivery Across Routes, Modalities, and Indications
What You Missed in 2025
- Brand New Investor Perspectives: Attendees gained insights on how they assess risk and opportunity, the role of clinical validation, and the impact of scalability, manufacturability, and IP strategy on funding decisions
- Two Tailored Streams: Participated in sessions focused on Systemic Delivery or Direct & Local Delivery. Featuring the latest innovations in receptor-mediated transcytosis, convection-enhanced delivery, focused ultrasound, and emerging modalities to ensure every session addressed your CNS drug delivery priorities
- Fresh Content from 18+ New Faces: We heard from world-class speakers driving CNS drug delivery innovation at Sanofi, UCB, Alnylam, Eli Lilly, JCR, Merck, and many more. They shared cutting-edge case studies, translational data, and practical strategies to overcome the blood-brain barrier and optimize targeted brain delivery
Your Peers Explored:
The latest clinical advancements in local delivery with insights from Biogen.
Explored strategies for delivering diverse therapeutic cargos using viral, non-viral, and chemistry-based platforms to targeted brain regions.
Collaboratively addressed challenges in off-target toxicity, formulation, and translatability to enhance the effectiveness and predictability of brain delivery.
Connected with a community of leaders from academia, biotech, pharma, and tech, sparking ideas and cross-sector collaboration alongside powerhouses like Biogen, Alnylam, Sanofi, Eli Lilly, and more.
Explored engineering and design innovations in device-mediated delivery systems and strategize ways to enhance their clinical scalability.
Attending Companies Include